Sanara MedTech (SMTI) EBIT (2010 - 2026)

Sanara MedTech has reported EBIT for 16 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 220.59% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $6.6 million (up 574.43% YoY), and the FY2025 full-year result was $7.3 million, up 480.26% from the prior year.
• EBIT for Q1 2026 stood at $2.6 million, up from $1.1 million in the prior quarter.
• The five-year high for EBIT was $6.5 million in Q4 2022, with the low at -$3.4 million in Q2 2022.
• Historically, EBIT has averaged -$59532.6 across 5 years, with a median of -$225995.0 in 2023.
• Annual changes were most pronounced in 2022 — EBIT tumbled 229.86% — and 2024, when it soared 1100.21%.
• Sanara MedTech's EBIT stood at $6.5 million in 2022, then sank by 103.45% to -$225995.0 in 2023, then soared by 1100.21% to $2.3 million in 2024, then sank by 53.53% to $1.1 million in 2025, then soared by 151.95% to $2.6 million in 2026.
• The last three EBIT figures came in at $2.6 million (Q1 2026), $1.1 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.